An observational study in Migraine, sponsored by Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine · Observational
The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world.
The main questions it aims to answer are:
[question 2] the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 173 is above the median of 130 across 299 observational studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →This is the only study on the registry with Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine as lead sponsor.
Counted across the registry records on this site, refreshed daily.
This study will be conducted in the headache clinic of Ruijin-hainan hospital. Participants meeting the inclusion and exclusion criteria will be enrolled continuously.
Exclusion Criteria:
this group would use Rimegepant 75mg ODT, use it when needed for 1year
Drug: Rimegepant 75 MG
Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Change From Baseline on the percentage of participants that are pain relief at 2 hours post-dose during the migraine attack
Pain Relief at 2 hours post-dose will be assessed using the number of subjects that report a pain level of moderate or severe at baseline and then report a pain level of none or mild at two hours post-dose.
Time frame: Difference between baseline and 2 hours post-dose of Rimegepant
Change From Baseline on percentage of participants that are pain relief at 0.5,1,24 and 48 hours post-dose during the migraine attack
Pain Relief at 0.5,1,24 and 48 hours post-dose will be assessed using the number of subjects that report a pain level of moderate or severe at baseline and then report a pain level of none or mild at 0.5,1,24 and 48 hours post-dose.
Time frame: Difference between baseline and 0.5, 1, 24 and 48 hours post-dose of Rimegepant
Change From Baseline on the percentage of subjects able to function normally, at 0.5, 1, 2, 24 and 48 hours post-dose, will be accessed by the Functional Disability scale
The ability to function normally will be measured using the number of subjects that self-report as "normal" on the Functional Disability scale
Time frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
Change From Baseline on the percentage of participants that are pain freedom at 0.5,1, 2, 24 and 48 hours post-dose during the migraine attack
Pain freedom will be assessed using the number of evaluable subjects that report no pain at 0.5,1,2,24 and 48 hours post-dose. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
Time frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
Change From Baseline on the percentage of participants that are freedom from Most Bothersome Symptoms MBS (nausea, phonophobia or photophobia) at 0.5,1,2,24 and 48 hours post-dose during the migraine attack
Freedom from Most Bothersome Symptom will be measured using the number of subjects that report the absence of their MBS (nausea, phonophobia or photophobia) and will measured as (0=absent, 1=present)
Time frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
Change From Baseline in the Mean Number of Migraine Days Per Month Over the 12 months follow-up period.
A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. (A month is defined as 4 weeks for the purpose of this protocol).The change from baseline was calculated as the number of monthly migraine days during the every 4 weeks of the 12 months follow-up period minus number of monthly migraine days of baseline.Baseline is defined as the number of migraine days during the last 28 days prior to the recruiting date.
Time frame: From baseline to 12 months follow-up period
Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v 2.1 (MSQ) total score and Headache Impact Test (HIT-6) total score at month 3,6,12 in the 12 months follow-up
The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks.The HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations.
Time frame: From baseline and month 3,6,12 in the 12 months follow-up
Plan to share: Undecided
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.